Business analysis and valuation of Traphaco Joint Stock Company (TRA-HOSE)
Abstract
As the oriental drugs has been gradually gaining sympathy and trust of users, oriental drugs makers continue to grow and thrive rapidly. Out of which, Traphaco is one
of the most outstanding companies which have already positioned themselves in the top high-growth firms. When an increasing number of investors may start to turn their attention to Traphaco, a crystal clear question emerges: whether people can reap good return by investing in this company. The thesis, therefore, has just appeared to propose an adequate answer by estimating the company’s intrinsic value and price of its stock.
To successfully do this, the thesis analyzed Traphaco’s financial statements and its key financial ratios. A forecast of the company’s prospect is then derived from the analysis earlier. Besides, the company’s strategies and overall performance of pharmaceutical industry are consulted as well to get more precise prediction.
Later, the estimation of firm’ stock value is achieved to put into comparison with the company’s current stock price. The thesis may ignore some unannounced strategies of the company and unexpected economic changes that occur later, but finally can reveal Traphaco satisfy all its shareholders. Since its stock price is
undervalued, the company’s stock is sufficient to help investors end with a profit.